Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...

Leerink Partners调整了对2Seventy Bio Inc. (NASDAQ: TSVT)的展望，将该股票的目标价从之前的15.00美元上调至25.00美元，同时维持"优于大市"评级。 此次调整是在KarMMa-9试验终止后做出的，该试验原本预计将成为自体BCMA CAR-T疗法Abecma收入增长的重要贡献者。 根据Leerink Partners的分析，尽管KarMMa-9试验终 ...

Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...

Will peptide-drug conjugates become the "next big thing" in targeted cancer therapy? (Endpoints News) Bristol Myers Squibb ...

NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...

KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...